Mukoaktivnye preparaty i obostrenie khronicheskoy obstruktivnoy bolezni legkikh (fokus na karbotsistein)


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

In recent years, increased interest in mucoactive drugs is caused by two reasons: better understanding of the pathophysiology of chronic obstructive pulmonary disease (COPD); in particular, it was found that the lungs are constantly secrete a variety of oxidants produced endogenously as a result of metabolic reactions, and exogenously in response to aeropollutant exposure, including components of tobacco smoke; and evidence that some of mucoactive drugs (N-acetylcysteine, carbocisteine) have antioxidant properties. In this context, special attention should be paid to carbocisteine (S-carboxymethylcysteine, also available carbocisteine lysine salt - S-carboxymethylcysteine lysinate) - mucoregulatory drug with anti-oxidant and anti-inflammatory properties, which are now widely used in the treatment of patients with COPD. The numerous clinical studies suggest that long-term (6-12-month) use of drug in COPD patients is accompanied by reduction of frequency of disease exacerbations and improvement of quality of life for patients.

Texto integral

Acesso é fechado

Sobre autores

A. Sinopal'nikov

Bibliografia

  1. Knowels MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest 2002;109:571-77.
  2. Fletcher CM, Jones NL, Burrows B, et al. American emphysema and British bronchitis. A standardized comparative study. Am Rev Respire Dis 1964;90:1-13.
  3. Barnes PJ. Chronic obstructive pulmonary disease. Overview. In: Encyclopedia of Respiratory Medicine. Eds. - GJ Laurent, SD Shapiro (eds.). Oxford, UK: Elsevier Ltd. 1st ed. 2006; 1:429-39.
  4. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89.
  5. Washko GR, Fan VS, Ramsey SD, et al. The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations. Am J Respir Crit care Med 2008;177:164-69.
  6. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J respire of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54.
  7. Nannini L, Cates C, Lasserson T, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. Cochrane Data-base Syst Rev 2007;4.
  8. Rennard S, Carverley PM, Goehringer U, et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast: the importance of defining different subsets of patients with COPD. Respir Res 2011;12:18.
  9. Calverley PM, Rabe K, Goehringer U, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomized clinical trials. Lancet 2009;374:685-94.
  10. Janda S, Park K, FitzGerald JM, et al. Statins in COPD: a systematic review. Chest 2009;136:734-43.
  11. Sethi S, Jones PW, Theron MS, et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res 2010;11:10.
  12. Balsamo R, Lanata L, Egan CG. Mucoactive Crit Care Med 2008;177:19-26.
  13. Direct cost to primary care of chronic bronchitis. Analysis of a prospective study. Aten Promaria 2001;27:388-94.
  14. Miravitlles M, Calle M, Soiler-Cataluna JJ. Clinical phenotypes of COPD: identification, definition and implications in guidelines. Arch Bronconeumol 2012;48:86-98.
  15. Wedzicha JA, Hurst JR. Chronic obstructive pulmonary disease. Acute exacerbations. In: Encyclopedia of Respiratory Medicine. Eds. GJ Laurent, SD Shapiro (eds.). Oxford, UK: Elsevier Ltd. 1st ed. 2006;1:439-43.
  16. Han MK, Martinez FJ. Pharmacotherapeutic approaches to preventing acute exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2011;8:356-62.
  17. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a oncedaily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005; 143:317-26.
  18. Tashkin DP, Celli B, Senn S, et al. A 4-year trial drugs. Eur Respir Rev 2010;19:127-33.
  19. de Boer WI, Yao H, Rahman I. Future therapeutic treatment of COPD: struggle between oxidants and cytokines. Int J Chron Obstruct Pulmon Dis 2007;2:205-28.
  20. Poole P, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Darabase Syst rev 2010;CD001287.
  21. Rogers DF. Mucoactive drugs for asthma and COPD: any place in therapy? Expert Opin Investig Drugs 2002;11:15-35.
  22. Havez R, Degand P, Roussel P, et al. Biochemical mechanism of action of cysteine derivatives on bronchial mucus. Poumon Coeur 1970; 26:81-90.
  23. Puchelle E, Girard F, Polu JM, et al. Effect of the mucoregulator S-carboxy-methyl-cysteine in patients with chronic bronchitis. Eur J Clin Pharmacol 1978;14:177-84.
  24. Colombo B, Turconi P, Daffonchio L, et al. Stimulation of Cl- secretion by the mucoactive drug S-carboxy-methylcysteinelysine salt in the isolated rabbit trachea. Eur Respir J 1994;7:1622-28.
  25. Asti C, Melillo G, Caselli GF, et al. Effectiveness of carbocysteine lysine salt monohydrate on models of airway inflammation and hyperresponsiveness. Pharmacol Res 1995;31:387-92.
  26. Carpagnano GE, Resta O, Foschino-Barbaro MP, et al. Exhaled interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monohydrate (SCMC-Lys). Eur J Pharmacol 2004; 505:169-75.
  27. Yasuda H, Yamaya M, Sazaki T, et al. Carbocysteine inhibits rhinovirus infection in human tracheal epithelial cells. Eur Respir J 2006;28:51-58.
  28. Suer E, Sayrac S, Sarinay E, et al. Variation in attachment of Streptococcus pneumoniae to human pharyngeal epithelial cells after treatment with S-carboxymethylcysteine. J Infect Chemother 2008;14:333-36.
  29. Guizzardi F, Rodighiero S, Binelli A, et al. S-CMC-Lys-dependent stimulation of electrogenic glutathione secretion by human respiratory epithelium. J Mol Med 2006;84:97-107.
  30. Garavaglia ML, Bononi E, Dossena S, et al. S-CMC-Lys protective effect on human respiratory cells during oxidative stress. Cell Physiol Biochem 2008;22:455-64.
  31. Zheng JP, Kang J, Huang SG, et al. Effect of carbocysteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomized placebo-controlled study. Lancet 2008;371:2013-18.
  32. Allegra L, Cordaro CI, Grassi C. Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, double-blind, placebo-controlled trial. Respiration 1996;63:174-80.
  33. Yasuda H, Yamaya M, Sasaki T, et al. Carbocysteine reduces frequency of common colds and exacerbations in patients with chronic obstructive pulmonary disease. J Am Geriatr Soc 2006;54:378-80.
  34. Maccio A, Madeddu C, Panzone F, et al. Carbocysteine: clinical experience and new perspectives in the treatment of chronic inflammatory diseases. Expert Opin Pharmacother 2009;10:693-703.
  35. Tatsumi K, Fukuchi Y. Carbocysteine improves quality of life in patients with chronic obstructive pulmonary disease. J Am Geriatr Soc 2007;55:1884-86.
  36. Rahman I. Antioxidant therapeutic advances in COPD. Ther Adv Respir Dis 2008;2:351-74.
  37. Pena LR, Hill DB, McClain CJ. Treatment with glutathione precursor decreases cytokine activity. JPEN J Parenter Enteral Nutr 1999;23:1-6.
  38. Woodhead M, Blasi F, Ewig S, and the ERS/ ESCMID Task Force. Guidelines for the management of adult lower respiratory tract infections. Clin Microbiol Infect 2011;17(6):1-59.
  39. Синопальников А.И., Романовских А.Г. Рекомендации по ведению взрослых пациентов с инфекциями нижних дыхательных путей // Клин. микробиол. антимикроб. химиотер. 2012. № 14(1).С. 4-16.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2012